C4 Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $26.0 million, compared to a net loss of $17.7 million for the same period in 2024. For the six months ended June 30, 2025, the company recorded a net loss of $52.3 million, up from $46.1 million in the prior year. Revenue from collaboration agreements decreased to $6.5 million for the second quarter, down from $12.0 million in the same quarter last year, primarily due to a significant decline in revenue from the Biogen collaboration, which had a milestone payment recognized in full during the second quarter of 2024.
Total operating expenses for the second quarter of 2025 were $35.0 million, compared to $33.4 million in the same quarter of 2024. Research and development expenses increased to $26.2 million from $23.8 million year-over-year, driven by higher clinical expenses related to ongoing trials for its lead product candidate, cemsidomide. General and administrative expenses also saw a slight decrease, totaling $8.8 million compared to $9.7 million in the prior year, largely due to reduced stock-based compensation expenses.
C4 Therapeutics has made strategic advancements, including the initiation of a Phase 1 clinical trial for CFT8919 in collaboration with Betta Pharma, which began in November 2024. The company also entered into new collaboration agreements with MKDG and Merck, which are expected to contribute to future revenues. As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling approximately $223.0 million, which it believes will be sufficient to fund operations for at least the next twelve months.
The company’s total assets decreased to $296.5 million as of June 30, 2025, down from $349.6 million at the end of 2024, primarily due to a reduction in marketable securities. C4 Therapeutics continues to face challenges typical of clinical-stage biopharmaceutical companies, including the need for additional financing to support ongoing research and development activities. The company has not yet generated revenue from product sales and does not expect to do so in the near future, relying instead on collaboration agreements for funding.
Looking ahead, C4 Therapeutics anticipates continued operating losses as it advances its clinical programs. The company is focused on its lead candidate, cemsidomide, for multiple myeloma and non-Hodgkin lymphoma, while also exploring additional product candidates and collaborations to enhance its pipeline. The management remains optimistic about the potential of its proprietary TORPEDO platform to deliver innovative therapies in the oncology space.
About C4 Therapeutics, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.